Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age3-70
SponsorPeking University People's Hospital
About this trial
To observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/NHL
Eligibility criteria
Qualifiers
The subject or guardian understands and voluntarily signs the informed consent form (ICF).
Male or female, aged 3-70 years at the time of signing the ICF (inclusive).
Expected survival of at least 12 weeks.
ECOG performance status of 0-2 at the time of ICF signing.
Disqualifiers
Epilepsy
Paralysis
Aphasia
Stroke
Trial design
Treatments tested in this trial
- CD5-targeted CAR-T cells
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Peking University People's Hospital
Lead sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Collaborator
Source ClinicalTrials.gov